Teva to Sell Generic Viagra in 2017 in Pfizer Settlement
This article is for subscribers only.
Generic Viagra will hit the U.S. market more than two years earlier than had been anticipated under a settlement reached by Teva Pharmaceutical Industries Ltd. and the maker of the impotence drug, Pfizer Inc.
Teva can enter the market on Dec. 11, 2017, and will pay patent royalties through the expiration of the Viagra patent in April 2020, New York-based Pfizer said in a statement. Other settlement terms weren’t disclosed.